Nuveen Asset Management, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$608,225
-16.3%
515,4450.0%0.00%
Q2 2023$726,777
-3.1%
515,445
-6.6%
0.00%
Q1 2022$750,000
+0.7%
551,993
+35.6%
0.00%
Q4 2021$745,000
-33.8%
406,930
-7.8%
0.00%
Q3 2021$1,126,000
-12.2%
441,591
-1.8%
0.00%
Q2 2021$1,283,000
+266.6%
449,911
+6.3%
0.00%
Q1 2020$350,000
-19.5%
423,265
-13.6%
0.00%
Q4 2019$435,000
-58.5%
489,811
-54.3%
0.00%
Q3 2019$1,049,0001,070,7510.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders